Tribunal finds discriminatory refusal of care for trans teen

A family physician in Delta, British Columbia, has been ordered to pay compensation after a tribunal determined that his refusal to administer a prescribed hormone blocker to a transgender teenager was discriminatory. The decision, issued by the B.C. Human Rights Commission, centers on an incident in March 2021 where Dr. Henry Ajaero declined to inject the patient with Lupron, citing religious and cultural objections. According to the ruling, the doctor failed to establish a legitimate conflict between his beliefs and the medical service requested.

The tribunal awarded $28,100 in damages, concluding that the physician’s conduct violated human rights protections. While Dr. Ajaero argued that administering the medication fell outside his scope of practice and conflicted with his faith, the decision noted that these standards were not reasonably necessary to achieve their purposes. The ruling emphasizes that the context of a busy clinical day does not justify denying medical services to a vulnerable youth based on gender identity.

Tribunal rejects religious exemption claim

In his defense, Dr. Ajaero testified that he had never previously interacted with a transgender person or administered Lupron, describing himself as uncomfortable and unprepared for the procedure. However, the tribunal noted that the medication was prescribed by an endocrinologist at the B.C. Gender Clinic specifically to pause puberty, rather than as a tool for gender reassignment. The decision clarified that the medication does not inherently conflict with the doctor’s stated belief regarding the creation of man and woman, thereby undermining the basis for his refusal.

According to the source GN geopolitics/rights (en-US), the tribunal highlighted that the doctor’s religious standards were likely developed quickly during a stressful period. The ruling distinguishes between an explanation for the decision and a justification for it, stating that while the circumstances explain the doctor's reaction, they do not validate the denial of care. The decision underscores the legal obligation to provide equitable medical services regardless of a patient's gender identity.

Impact on patient care continuity

The teenager, referred to as Child Q in the decision, had come out as transgender in late 2020 and struggled with mental health issues as she entered puberty. Her family preferred to have the Lupron injections administered by a doctor rather than at home, as the medication requires regular administration every three to four weeks. The refusal by her family doctor severed a critical point of contact in her healthcare network, leaving the patient and her mother without further communication with the practice outside of legal proceedings.

The tribunal described Child Q as a brave and sensitive individual who viewed the start of her medication as one of the best days of her life. By denying the injection, the physician interrupted a medical process that was intended to provide time for the teen to consider options regarding her gender identity. The decision reflects a broader concern about the availability of affirming care for transgender youth within primary care settings, where trust and continuity are essential for effective treatment.

Forward questions on medical accommodation

This ruling sets a precedent for how religious and cultural objections are weighed against the duty of care in medical practice. It suggests that personal discomfort or lack of prior experience with a specific demographic is insufficient grounds for refusing prescribed treatments. The decision invites scrutiny on how physicians balance their personal beliefs with professional obligations, particularly when dealing with vulnerable populations such as transgender adolescents.

Observers will likely watch for similar cases across other jurisdictions to see if this interpretation of human rights law gains traction. The outcome raises questions about the availability of alternative providers when a primary care physician refuses care, and whether systemic changes are needed to ensure that transgender youth can access necessary medications without facing discrimination. The financial penalty serves as a tangible consequence, but the broader implication lies in the reinforcement of non-discrimination standards in healthcare.